CDKN2A and neoplasm: In fact, the study of Raabe et al. on 66 PAs evidenced that the loss of expression is present in 14% of cases and the outcome analyses confirmed that 33% of patients losing p16 expression died from their disease, compared to the 3.6% of deceased patients still expressing p16 in their tumor [30].